Last reviewed · How we verify
néfopam
Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.
Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia. Used for Moderate acute and postoperative pain, Chronic pain conditions.
At a glance
| Generic name | néfopam |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Drug class | Non-opioid analgesic; monoamine reuptake inhibitor |
| Target | Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Nefopam works primarily by blocking the reuptake of norepinephrine and dopamine at presynaptic terminals, increasing their synaptic concentrations and enhancing pain modulation pathways. Unlike opioids, it does not bind to opioid receptors and has a distinct mechanism that makes it useful as a non-opioid alternative for moderate pain relief. It also has mild anticholinergic and sympathomimetic properties that contribute to its analgesic effects.
Approved indications
- Moderate acute and postoperative pain
- Chronic pain conditions
Common side effects
- Sweating
- Tachycardia
- Tremor
- Dizziness
- Nausea
- Insomnia
Key clinical trials
- Effects of Nefopam on Hyperalgesia After Cardiac Surgery (PHASE2, PHASE3)
- Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- néfopam CI brief — competitive landscape report
- néfopam updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI